Carboxylic acids and salts or anhydrides thereof (A61K47/12)

Oral pharmaceutical compositions of testosterone esters and method for testosterone shortage treatment with their use // 2642244
FIELD: pharmacology.SUBSTANCE: invention concerns an oral pharmaceutical composition for testosterone shortage treatment for men, containing testosterone undecanoate dissolved in a medium containing at least one lipophilic surfactant and at least one hydrophilic surfactant with a ratio of the total number of lipophilic surfactants to the total number of hydrophilic surfactants (in/out), being in an approximate range from 6:1 to 3.5:1, while the dissolved testosterone undecanoate ranges from 18 to 22 wt % of the composition. The invention also relates to composition application for production of a drug for treatment of testosterone shortage or its symptoms in men and a treatment method, which includes oral intake of an effective amount of the pharmaceutical composition.EFFECT: application of the invention provides an opportunity to achieve a higher bioavailability, providing an effective therapeutic product based on testosterone for oral introduction, which can increase the levels of testosterone in the blood serum to clinically effective values, efficient oral testosterone therapy.23 cl, 10 tbl, 5 ex, 5 dwg

Pharmaceutical composition containing biotin and method for its production // 2639488
FIELD: pharmacology.SUBSTANCE: group of inventions refers to pharmaceutical compositions for polyneuropathy prevention and treatment as a solid dosage form with extended release, comprising Biotin - 40-60 wt % as an active agent, as well as Methocel K100 LV - 14-21 wt %, Methocel K4M - 5-10 wt %, microcrystalline cellulose (MCC) - 7-18 wt %, copovidone - 1.5-3 wt %, colloidal silicon dioxide - 0.4-1 wt % and a pharmaceutically acceptable stearic acid salt - 0.6-1 wt %, as well as to a method for its production, according to which Biotin, Methocel K4M, Methocel K100 LV, MCC and copovidone are sieved and mixed until homogeneous, stearic acid salt, colloidal silicon dioxide are mixed, the mixture is compacted by rolling, colloidal silicon dioxide is added and mixed together with pre-compacted grains, followed by addition of stearic acid salt, stirring and formation a solid dosage form.EFFECT: creation of a new medicinal composition with high technological properties, high stability and reproducible kinetics of active agent release.9 cl, 8 ex, 5 tbl, 1 dwg
Solid oral pharmaceutical composition of s1p agonist or its pharmaceutically acceptable salt, method for its production and methods for treatment and reduction of frequency of clinical exacerbations of multiple sclerosis // 2639424
FIELD: pharmacology.SUBSTANCE: solid oral pharmaceutical composition consists of phignolimide hydrochloride in an amount of 0.4-0.65 mg, pregelatinized starch in an amount of 145-155 mg and magnesium stearate in an amount of 1.0-2.0 mg. The composition can be presented in the form of a pill or a capsule. The composition intended for treatment of relapsing-remitting multiple sclerosis, to reduce the frequency of clinical exacerbations of the disease and reduce the risk of disability progression in relapsing-remitting multiple sclerosis. The composition is administered orally in a dose of 500 μg, once a day.EFFECT: composition according to the invention is characterized by a high homogeneity of the active substance dosage, stability for prolonged storage and is capable of disintegrating and releasing the active substance rapidly during oral administration.5 cl, 10 tbl, 8 ex

Transdermal pharmaceutical compositions containing active agents // 2639087
FIELD: pharmacology.SUBSTANCE: invention is a sustained release pharmaceutical composition for topical administration to the skin surface, which comprises: a pharmaceutically active agent selected from the group consisting of estrogens, antiestrogens, androgens, antiandrogens, progestins, and mixtures thereof, 0.01-5 wt % of the total weight of the pharmaceutical composition of the fatty acid ester selected from the group consisting of ethyl oleate, isopropyl myristate, isopropyl isostearate, isopropyl palmitate, ethyl octanoate, ethyl dodecanoate, ethyllinoleate, ethyl palmitoleate, ethyl isostearate and ethyllleleate, water, C2-C6 mono-alcohol selected from the group consisting of ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol and mixtures thereof, a fatty acid selected from the group consisting of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, isostearic acid, palmitoleic acid, linoleic acid and linolenic acid, and from 0.05 to 5 wt % of gelling agent, wherein the weight ratio of the fatty acid ester in the composition to the total active agent in said composition is at least 4:1 (fatty acid ester:active agent), preferably 4:1 to 20:1.EFFECT: invention provides sustained release, corresponding delivery profiles in the concentration range of active agents, and reproducibility from application to application and from patient to patient.21 cl, 11 ex, 10 dwg, 24 tbl
Gel with antifungal action (versions) // 2638798
FIELD: pharmacology.SUBSTANCE: invention is an antifungal gel containing pectin, glycerin, carbopol, octopirox, purified water, extracts of celandine, yarrow, St. John's wort, calendula flowers, peppermint and marigold leaves, essential oils of melilot, fir, lavender and clove, 10% ammonium water, nipagin, nipasol, PEG-stearate and vegetable oil, or an antifungal gel containing pectin, glycerin, carbopol, octopirox, purified water, extracts of celandine, yarrow, St. John's wort, absinthium, calendula, chamomile flowers, peppermint leaves, licorice root, rosehips, fennel, thyme, cumin, pine buds, essential oils of melilot, fir, lavender and clove, euxyl, empicol, PEG-stearate and vegetable oil, or an antifungal gel containing containing pectin, glycerin, carbopol, octopirox, purified water, extracts of celandine, yarrow, St. John's wort, absinthium, calendula, chamomile flowers, peppermint leaves, licorice root, rosehips, fennel, thyme, cumin, pine buds, essential oils of melilot, lavender, clove and cedarwood, euxyl, empicol, Sibo salcare SC-91 and vegetable oil, or an antifungal gel containing pectin, glycerin, carbopol, octopirox, purified water, extracts of celandine, yarrow, St. John's wort, absinthium, calendula, chamomile flowers, peppermint leaves, licorice root, rosehips, fennel, thyme, cumin, pine buds essential oils of melilot, fir, lavender, clove and fennel, euxyl, empicol, Sibo salcare SC-91 and vegetable oil, with components in gels being in a certain ration, wt.%.EFFECT: increased effectiveness of treatment of skin fungal diseases, reduced duration of treatment, creation of a gel that is easy to use with application of herbal phytocompositions with simultaneous creation of conditions for its comfortable use.4 cl, 4 ex, 3 tbl

Treatment of inflammatory damages in case of rosazea using ivermectin // 2633481
FIELD: pharmacology.SUBSTANCE: invention is a method for inflammatory damages treatment in case of rosacea in a subject in need thereof, comprising topical administration of a pharmaceutical composition containing 0.5% to 1.5% by weight of ivermectin and a pharmaceutically acceptable carrier once a day to the skin area affected by inflammatory damages at rosacea, where, 2 weeks after the initial administration of the pharmaceutical composition, a significant reduction in the amount of inflammatory damages is observed.EFFECT: significant reduction in the number of inflammatory damages at rosacea two weeks after the initial application, more effective treatment, statistically significant remission and reduced adverse skin reactions.15 cl, 5 ex, 8 tbl, 13 dwg

Papulopustular rosacea treatment by ivermectin // 2633076
FIELD: pharmacology.SUBSTANCE: invention is a method for treatment of papulopustular rosacea in a subject in need thereof, comprising topical application of a therapeutically effective amount of a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier, once a day, to a region of skin afflicted with papulopustular rosacea, wherein the treatment results in a significant reduction in the number of inflammatory foci within 2 weeks after the initial application of the pharmaceutical composition.EFFECT: significant reduction in the number of inflammatory foci two weeks after the initial application without joint application of another active agent, more effective treatment, and a longer remission, a reduction in adverse skin reactions.16 cl, 12 dwg, 7 tbl, 4 ex

Viruses inactivation of with application of caprylate // 2633059
FIELD: pharmacology.SUBSTANCE: method for blood plasma albumin preparation for pharmaceutical use includes the following steps: (i) obtaining an eluate of fraction IV-1 or a Cohen F fraction; (ii) adjustment of the albumin solution concentration to a value of less than 5 wt %; (iii) solution pH adjustment to a pH of 5 or less; (iv) caprylic acid (octanoic acid) or sodium caprylate addition to a concentration of 20 mM; (v) solution temperature increasing to 27-30°C; (vi) solution incubation for 30-120 minutes, followed by solution filtration; ultrafiltration and diafiltration; solution volume composition and increasing; sterilisation, containers filling and albumin pasteurization. A method for viruses inactivation in an albumin-containing solution comprises the following steps: (i) adjustment of albumin solution concentration to a value of less than 5 wt %; (ii) solution pH adjustment to a pH of 5 or less; (iii) caprylic acid (octanoic acid) or sodium caprylate addition; (iv) solution temperature increasing to 27-30°C and (v) solution incubation for 30-120 minutes.EFFECT: reduced risk of blood-borne viruses transmission, reduced time of albumin purification.16 cl, 7 dwg, 4 tbl, 4 ex
Soft chewing pharmaceutical products // 2632965
FIELD: pharmacology.SUBSTANCE: method of manufacturing a soft chewable veterinary pharmaceutical product containing as ingredients: an isoxazoline compound, pamoic acid or a pharmaceutically acceptable salt thereof, a liquid component, a forming agent and optionally one or more excipients in a forming machine, comprises mixing the ingredients into a dough Mixing dry ingredients, followed by the addition of liquid components to form a thoroughly mixed mixture, unloading the dough-like mass from that the mixer into a suitable container for further manufacturing individual dosage units by using a moulding machine, mould filling doughy mass and removing dough from the mould, wherein the mixing step, from 1.5 to 30% of pamoic acid or a pharmaceutically acceptable salt or pamoate salt of the active pharmaceutical ingredient is mixed with the other ingredients. The pharmaceutically acceptable salt of the pamoic acid is sodium pamoate. The soft chewable pharmaceutical product obtained by the process of the invention is used in the manufacture of a medicament for controlling the infection of an animal with parasitic insects or acarids.EFFECT: method of manufacturing a soft chewable veterinary pharmaceutical product provides ease in the manufacture of the product.9 cl, 7 tbl, 4 ex
Delayed release pharmaceutical composition containing asparaginates // 2632713
FIELD: pharmacology.SUBSTANCE: drug can be used in therapy, in particular in cardiology, and in sports medicine. Preferably, the pharmaceutical composition for oral use in the form of a pill contains hemihydrate, magnesium aspartate dihydrate, microcrystalline cellulose, sodium croscarmellose, aerosil, stearic acid in the potassium asparaginate; the pill shell contains the pH-dependent polymer Eudragit, polyethylene glycol, talc, titanium dioxide. A method for manufacture of a tablet with asparaginates is also described. The composition is characterized by delayed, after 2 hours, release of active ingredients and subsequent rapid release of these active substances in a therapeutically active concentration within 20-30 minutes.EFFECT: reduced side effects on the gastric mucosa.16 cl, 11 dwg, 1 tbl, 11 ex
Sustainable structures of antithrombocytic agents, omega-3 fatty acids and amylose in soft gelatin capsules // 2630606
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition of acetylsalicylic acid or a pharmaceutically acceptable salt thereof, omega-3 fatty acids, a pharmaceutically acceptable organic acid and amylose or starch containing 50 wt % to 70 wt % of amylose in soft gelatin capsules.EFFECT: invention allows to obtain a composition with improved stability over time during storage, compared to soft gelatin capsules including pregelatinized starch in the capsule and in the core.8 cl, 13 tbl, 8 ex

Crystalline micro particles of beta-agonist, coated with fatty acid // 2629085
FIELD: chemistry.SUBSTANCE: crystalline microparticles consisting of formoterol or its pharmaceutically acceptable salts and myristic acid in amount of 1.0 to 2.0% by weight are described. Myristic acid forms continuous film on surface of microparticles. Crystalline microparticles are used in production of pharmaceutical aerosol compositions in the form of suspension in liquefied propellant gas or in the form of powder compositions. Method of producing microparticles and metered-dose inhaler under pressure filled with aerosol composition has been also described. Crystalline microparticles are used for prevention and/or treatment of respiratory disease, such as asthma or chronic obstructive pulmonary disease.EFFECT: crystalline microparticles of the invention are characterized by improved stability and composition of such particles with improved aerosol characteristics.9 cl, 1 dwg, 4 tbl, 6 ex

Composition including amlodipine and losartan having improved stability // 2628538
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for cardiovascular disorders prevention and treatment is described. The said composition comprises amlodipine besylate in an amount of 1.7 to 1.72 wt %, potassium losartan in an amount of 12.22 to 12.37 wt %, and propyl gallate in an amount of 0.01 wt %, based on the total weight of the composition. The said composition has the form of a two-layer pill having two separate layers consisting of an amlodipine layer containing amlodipine besylate and propyl gallate and a layer of losartan containing potassium losartan.EFFECT: improved composition stability in combination with simplicity of preparation.6 cl, 21 tbl, 2 dwg, 5 ex

Pharmaceutical composition for histone deacetylase inhibitors // 2625758
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for topical application is shown. It comprises of a therapeutically effective amount of active pharmaceutical ingredient (API) - a compound of the structural formula of at least one acidifying agent and a base carrier comprising of at least one pharmaceutically acceptable nonaqueous solvent. The acidifying agent is separated from citric acid, acetic acid and phosphoric acid. The measured pH value of the pharmaceutical composition is from 3 to 5. Preferably, the pharmaceutically acceptable nonaqueous solvent is a mixture of ethanol and propylene glycol. Also, a kit for preparing a pharmaceutical composition and a method for treating a proliferative, immune and skin diseases in a subject are desribed. The values of n, R1 and R2 in the structural formula (I) are defined in the claims.EFFECT: stabilized pharmaceutical composition is obtained.26 cl, 1 dwg, 18 tbl, 3 ex
Clozapine tablets with delayed release and method of obtaining thereof // 2624229
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to field of chemical-pharmaceutical industry, namely to pharmaceutical composition in form of tableted form with delayed release, which contains 30-40 wt % of clozapine as active component and additional substances: 20-35 wt % of Methocel K100 LV, 10-15 wt % of Methocel K4M, 12-30 wt % of microcrystalline cellulose, 2-3 wt % of copovidone, 0.5-1 wt % of colloidal silicon dioxide and 0.5-1 wt % of pharmaceutically acceptable salt of stearic acid, as well as to method of obtaining said pharmaceutical composition.EFFECT: group of the inventions provides obtaining clozapine tablets, possessing stability and reproducible kinetics of delayed release of active substance.8 cl, 4 ex, 4 tbl, 3 dwg
Composition 18f- flutsiklovina in citrate buffers // 2623163
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition is described, comprising [18F]-FACBC (1-amino-3-[18F]-ftorciklobutan-1-carboxylic acid), a citrate buffer, 1-amino-3-gidroxiciklobutan-1-carboxylic acid and has pH of 4.0-5.0. Also the method for preparing the composition is described.EFFECT: composition is resistant to degradation.18 cl, 1 ex
Antibacterial composition in form of suppository and method of its preparation // 2622762
FIELD: pharmacology.SUBSTANCE: invention is an antibacterial composition in the form of a suppository and a method of its preparation, wherein the composition comprises a liquid substance of bacteriophages containing at least three bacteriophages with a titre of at least 2⋅108 BFU per suppository of each strain, suppository base, including witepsol or tallow of type A, as well as Tween-80, wherein the composition components are in a certain ratio, in % per 1 suppository.EFFECT: systemic antibacterial effect and maintenance of initial high phage lysate titre.2 cl, 2 dwg, 7 tbl, 5 ex, 3 dwg
Stabilized pemetrexed composition // 2620341
FIELD: pharmacology.SUBSTANCE: composition contains pemetrexed or a pharmaceutically acceptable salt thereof as an active ingredient, N-acetyl-L-cysteine and sodium citrate, wherein the concentration ratio is -30 : 0.15 - 2.0 : 1.0 - 15.0, respectively. The liquid composition can be stored in a solution state. The composition is an injectable liquid composition in an airtight container. The composition is ready for use.EFFECT: combined use of pemetrexed, N-acetyl-L-cysteine and sodium citrate provides a composition that is highly stable and maintained in a clear solution without precipitation during storage.5 cl, 1 dwg, 12 tbl, 16 ex
Composition based on lecithine // 2620250
FIELD: pharmacology.SUBSTANCE: invention is a composition based on lecithine for transdermal delivery of biologically active substances, consisting of lecithin in the composition of a phospholipid concentrate, liquid paraffin and water, characterized by additional content of oleic acid, fatty oil selected from avocado oil, argan oil, jojoba oil, grape seed oil and essential oil selected from tea tree oil, lavender oil, rose oil, with the ingredients in the composition being in a certain wt % ratio.EFFECT: expanded arsenal of means for transdermal delivery, obtaining of a thermodynamically stable system with droplets of nanometer size while maintaining the level of solubilization capacity in water.1 dwg, 5 tbl, 4 ex
Solid drug form of indinavir with immediate release and method of obtaining thereof // 2616267
FIELD: pharmacology.SUBSTANCE: group of inventions relates to a solid form of indinavir sulfate, which is a capsule containing 67-79 wt % of indinavir sulfate, 10-20 wt % of lactose monohydrate, 7.7-15 wt % of Prosolv, 0.5-3 wt % of sodium croscarmellose (primellose) 0.5-1 wt % of stearic acid and/or its salt; and a method for its production, according to which indinavir sulfate, lactose monohydrate, croscarmellose sodium and Prosolv are mixed, dusted with stearic acid and/or its salt, encapsulated with simultaneous capsules dedusting and polishing.EFFECT: prompt active agent release and reduced timing of therapeutic effect.5 cl, 3 tbl

Stable pharmaceutical composition for oral administration comprising levocetirizine, or pharmaceutically acceptable salt thereof and montelukast or pharmaceutically acceptable salt thereof // 2614382
FIELD: medicine, pharmacy.SUBSTANCE: this present invention relfers to a pharmaceutical composition in the form of a capsule for oral administration for asthma or allergic rhinitis prevention or treatment. The composition comprises: (a) the first fraction of particles in the form of mini-pill comprising levocetirizine, or pharmaceutically acceptable salt thereof and organic acid; and (b) the second fraction of particles in the form of mini-pill comprising montelukast or pharmaceutically acceptable salt thereof. The organic acid is citric acid, tartaric acid, succinic acid or ascorbic acid. The organic acid is present in the amount of 100 parts by weight per 100 parts of levocetirizine. The said first and second particle fractions are physically separated and filled into the capsule. A method for pharmaceutical capsule composition production is also described. The pharmaceutical composition of this invention inhibits the production of related contaminants of levocetirizine and montelukast and provides good stability.EFFECT: invention expands the product range of drugs for allergic rhinitis or asthma prevention or treatment.9 cl, 3 dwg, 4 tbl, 6 ex

Stable liquid pharmaceutical preparations of fused protein tnfr: fc // 2614257
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, namely to stable pharmaceutical compositions of fused protein TNFR: Fc. Pharmaceutical compositions and kits for their application of different physical stability TNFR:Fc are obtained by using the citrate buffer system at a concentration of 25 to 120 mM and amino acid selected from the group consisting of proline and lysine, and their pharmaceutically acceptable salts at a concentration of 15 to 100 mM as a stabilizer.EFFECT: invention allows stability of pharmaceutical compositions of etanercept for long-term storage.50 cl, 1 dwg, 17 tbl, 3 ex

Tablets of clozapine with sustained release // 2613192
FIELD: pharmacy.SUBSTANCE: group of inventions relates to a pharmaceutical formulation of clozapine with sustained release in the form of tablets, film coated, containing 30.0-50.0 wt % of clozapine, 20.0-30.0 wt % of microcrystalline cellulose, 4.0-6.0 wt % of lactose monohydrate, 15.0-25.0 wt % of hydroxypropyl methylcellulose HPMC K15M, 1.0-3.0 wt % of hydroxypropyl methylcellulose HPMC 2910, 1.0-3.0 wt % of colloidal silicon dioxide, 0.05-1.5 wt % of pharmaceutically acceptable salts of stearic acid and 2.0-4.0 wt % of film coating which comprises polyvinyl alcohol, titanium dioxide, macrogol and acceptable dyes or a mixture Opadry II yellow; as well as to a process for preparing such a pharmaceutical composition.EFFECT: obtaining a stable pharmaceutical composition of clozapine in the form of tablets with sustained release and stable technological properties, as well as reproducible release kinetics of the active substance.9 cl, 5 ex, 1 tbl, 2 dwg
ethod for preparation of drug with locally-acting erythropoietin // 2611401
FIELD: medicine.SUBSTANCE: for method implementation, a film mass containing: 20.0 g of Na CMC 3% aqueous solution; 1.5 g of glycerol; 0.5 g of PEG 400; 0.006 g sorbic acid; EPO 1000 ME, is prepared. The film is stirred, poured into a mold and allowed to dry for 72 hours at the room temperature. The film is firmly fixed on the wound surface, absorbs the fluid, creating a moist environment in the wound, thereby facilitating early granulation. Plasticity provides atraumatic effect.EFFECT: potentiation of therapeutic effect, reduced microbial contamination, exact dosage of drug, which eliminates the possibility of overdoses and unwanted side effects.7 ex, 2 tbl
Water-soluble composition, possessing anti-tumour activity and method for obtaining thereof // 2611362
FIELD: medicine.SUBSTANCE: composition contains, wt %: soloxolon methyl 4.0-40.0; PEG with molecular weight 4000 Da - 40.0-57.4; β-glycine - 10.0-56.0. The invention also deals with method for obtaining composition, the method includes dissolution of soloxolon methyl and PEG in tert-butyl alcohol with ultrasonic impact and simultaneous heating of mixture to 45-50°C for 5-30 minutes until components are completely dissolved, after that addition of β-glycine and re-exposure of mixture to ulrrasound for 7-10 min, freezing and exposure of the obtained suspension at temperature -20°C for 4 hours, with the following lyophilic drying first at temperature -20°C until pressure in chamber drops lower than 17 mtorr, then at temperature 30°C for 2 hours.EFFECT: increase of water-solubility and anti-tumour activity of composition.2 cl, 3 dwg, 2 tbl, 7 ex

Compositions of recombinant furine // 2610436
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns stabilized aqueous compositions of recombinant furine, wherein compositions contain recombinant furine, pharmaceutically acceptable salt, calcium, sugar or sugar alcohol, non-ionic surfactant and buffer substance.EFFECT: group of inventions provides preserving more furine activity and content of monomer furine at simultaneous reduction of aggregation during storage and/or action of mechanical load.42 cl, 49 dwg, 22 tbl, 8 ex

Liquid dosage form of fenspiride and production method thereof // 2607965
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and represents liquid dosage form of fenspiride hydrochloride in form of syrup, including fenspiride hydrochloride, methyl parahydroxybenzoate, propyl parahydroxybenzoate, potassium sorbate, sodium citrate, citric acid monohydrate, sodium saccharinate, noncrystallizing liquid sorbitol, glycerin, honey flavoring agent, fruit flavoring agent, dye E110 and purified water, wherein ingredients of the dosage form are taken in certain proportions, g/100 ml.EFFECT: invention provides extending range of medications, which are liquid dosage forms of fenspiride hydrochloride, stable and long-term storable without use of sucrose.2 cl, 14 dwg, 9 tbl
Liquid pharmaceutical composition containing nitizinone // 2605301
FIELD: medicine.SUBSTANCE: invention refers to medicine and concerns liquid pharmaceutical composition applicable for oral administration, which involves suspension of effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitizinone) and buffer based on citric acid with pH in range from 2.5 to 3.5. Said composition is used for treating disorders and diseases, in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, for example, genetic tyrosinemia type I.EFFECT: invention provides stable liquid composition of nizitinone, which is adapted for introduction in children.20 cl, 7 ex, 12 tbl

Live vaccine for preventing influenza and preparation method thereof // 2604414
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to immunology, and is designed to manufacture liquid form influenza vaccine. Live vaccine in liquid form for preventing influenza includes flu strains of type H1N1 H3N2, B and a stabilizer. Stabilizer is represented by a complex consisting of gelatin, disodium salt of ethylenediamine tetraacetic acid with maltose, at the following content in a 0.5 mg dose: flue strain of subtype H1N1 and H3N2 with specific activity of not less than 106.9 EID50; flue strain of type B with specific activity of not less than 106.4 EID50; gelatine - 4.5-5.5 mg; disodium salt of ethylenediamine tetraacetic acid - 0.045-0.055 mg; maltose - 0.45-0.55 mg. Group of inventions also relates to a method for producing the said influenza vaccine.EFFECT: use of this group of inventions enables to obtain a live influenza vaccine in liquid form with high degree of purification from ovalbumin and impurity proteins, as well as promotes preservation of specific activity of vaccine during storage.2 cl, 2 tbl

ethod of producing water-soluble lyophilisate of 4-(3-oxo-3-ethoxypropanoyl)amino)benzoic acid possessing anti-ischemic and antioxidant activity // 2602665
FIELD: pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a method of producing a water-soluble lyophilisate, involving producing a combined solution of an active substance and a compound containing hydroxyl and amino groups (amino alcohol), characterized by that the active substance is 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid (EPABA) possessing anti-ischemic and antioxidant activity. Amino alcohol is selected from a group of N-methylglucamine or tris(hydroxymethyl)aminomethane; herewith the said substance and amino alcohol taken in the molar ratio from 1:1 to 1:10 are dissolved in water, the solution is added with an acid agent up to pH 6.8-7.5, neutral solution is filtered, frozen and dried by sublimation.EFFECT: invention enables to obtain water-soluble stable neutral lyophilisates of EPABA corresponding to process requirements of preparations for parenteral administration.3 cl, 4 dwg, 4 tbl, 2 ex

Drug preparation based on indole-3-carbinol with increased epigenetic activity // 2601893
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and can be used for production of medicinal agents, required in therapy of diseases of the reproductive system (pathology of mammary glands, uterus, endometrium). Therapeutic agent possessing epigenetic activity contains indole-3-carbinol and excipients: lactose, microcrystalline cellulose, modified corn starch, magnesium stearate or calcium stearate, enclosed in a capsule, which are made from hydroxypropyl methylcellulose, in the following quantity in one capsule, g: indole-3-carbinol 0.10-0.20; lactose 0.10-0.15; corn starch modified 0.05-0.15; microcrystalline cellulose 0.5-0.15; magnesium stearate or calcium stearate 0.001-0.004.EFFECT: invention allows to increase efficiency of release of indole-3-carbinol of dosage form and its conversion into diindolylmethane, which implements its diindolylmethane activity.1 cl, 3 dwg, 4 ex

Tableted drug based on the extract of alchemilla vulgaris // 2599020
FIELD: medicine.SUBSTANCE: invention relates to tableted drug for the treatment of syndrome of increased blood viscosity. Agent includes 6 wt% of thick extract of Alchemilla vulgaris, obtained by evaporation of alcoholic extract to a residual humidity of 25 %, 46.8 wt% of glucose, 46.8 wt% of lactose, 0.1 wt% of calcium stearate and 5 % aqueous solution of methylcellulose - the rest.EFFECT: invention ensures production of tablets with high strength, high stability during storage and satisfying the requirements of the current pharmacopoeia.1 cl, 2 tbl, 1 ex

Agent with immunomodulating properties for prevention of atherosclerosis // 2597161
FIELD: medicine.SUBSTANCE: invention relates to an agent with immunomodulating properties for prevention of atherosclerosis. Above agent contains 21 wt% of dried garlic powder, 21 wt% of dried Rhaponticum carthamoides powder, 21 wt% of powder of dried green tea leaves, 24 wt% of milk sugar (lactose), 7.8 wt% of stearic acid and 5.2 wt% of medical polyvinylpyrrolidone.EFFECT: invention has immunomodulatory action, which manifests itself in depolarisation of macrophages, hypolipidemic action, antioxidant activity and thrombolytic action.1 cl, 2 dwg, 2 tbl

Lyophilised preparation of cytotoxic dipeptides // 2597154
FIELD: pharmaceutics.SUBSTANCE: invention relates to a novel pharmaceutical Lyophilised preparation containing cytotoxic dipeptide, such as melphalan ftorfenamid hydrochloride, and saccharose, methods for preparing it, compositions containing Lyophilised pharmaceutical preparation and use thereof in treating malignant tumours.EFFECT: new preparation.15 cl, 21 dwg, 14 tbl, 5 ex

Pharmaceutical compositions containing dgat1 inhibitor // 2595866
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a pharmaceutical composition in form of a tablet containing a) therapeutically effective amount of sodium salt (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, b) sodium lauryl sulphate as a surfactant with properties of lubricant substance in amount of 0.1 to 5 %, c) low-substituted hydroxypropyl cellulose in dry binder with properties of baking powder in amount of 2 to 20 %, d) mixture of microcrystalline cellulose and anhydrous lactose as filler in ratio of 1:5 to 1:1 and e) sodium starch glycolate as a disintegrant in amount of 1 to 10 % by weight of tablet before application of film coating. Invention also relates to a method of preparing a pharmaceutical composition and use thereof as a medicinal agent.EFFECT: compositions demonstrate compression profile with a wide hardness window, which provides acceptable brittleness, hardness, decomposition and dissolution time and sufficient stability to achieve rational storage life.10 cl, 10 ex

Antiviral and immunostimulating drug // 2593570
FIELD: pharmaceutics. SUBSTANCE: described are 3 versions of antiviral and immunostimulating drugs in form of a film-coated tablet, consisting of active substance methylphenylthiomethyl-dimethylaminomethyl-hydroxybromoindole carboxylic acid ethyl ester (umifenovir), auxiliary substances of tablet-core and film shell. EFFECT: higher storage stability of said drug. 18 cl, 4 tbl

Drug dosage form containing 6'-fluoro-(n-methyl-or n, n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1, 1'-pyrano[3, 4, b]indole]-4-amine // 2589830
FIELD: medicine.SUBSTANCE: invention relates to medicine. Disclosed is a therapeutic dosage form for pain management, which contains 6'-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'N-spiro[cyclohexane-1,1'-pirano [3,4,b]indole]-4-amine or its physiologically acceptable salt and self-emulsifying preparation containing surfactant having hydrophilic-lipophilic balance (HLB) at least of 10 and oil, wherein oil is selected from group comprising saturated C8-C14 fatty acids, unsaturated C8-C18 fatty acids and their esters, mixture of saturated and unsaturated C8-C14 fatty acids, triglycerides of fatty acids, esters of propylene glycol and fatty acid. Drug dosage form is intended for introduction of twice a day, once a day or less frequently.EFFECT: technical result consists in the immediate release 6'-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'N-spiro[cyclohexane-1,1'-pirano[3,4,b]indole]-4-amine of the dosage form, in good bioavailability, despite low solubility in water and providing a long period of semi-elimination from body.13 cl, 1 dwg, 28 tbl

Pharmaceutical composition for oral administration with improved solubility and/or absorbability // 2589701
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a pharmaceutical composition for oral administration containing 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide, its salt or solvate as active pharmaceutical ingredient and fumaric acid as acid additive. Fumaric acid is contained in an amount of 0.25 to 5 weight fractions on the weight ratio of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamid.EFFECT: also described is method of stabilization, improve solubility and improved intestinal absorption of 4-((1-methyl pyrrole-2-yl)carbonyl)-N-(4-(4-morpholine-1-yl-carbonylpiperidin-1-yl)phenyl)-1-piperazincarboxamide by adding of fumaric acid to pharmaceutical composition.12 cl, 5 dwg, 8 tbl, 9 ex

Stable composition of antibody specifically bound with her2 receptors and preparation method thereof // 2589691
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and biotechnology, namely concerns new stable composition of antibody specifically bound with HER2 receptors in dried form, which can be recovered by solvent, and in form of concentrated solution, as well as method for preparing composition.EFFECT: invention can be used for creation of finished dosage form of preparation, as well as for preparing solution for infusions used for treating HER2-positive tumours.9 cl, 1 dwg, 3 tbl, 21 ex

Tablet quetiapine with prolonged release and synthesis method thereof // 2588840
FIELD: medicine; pharmaceuticals.SUBSTANCE: pharmaceutical composition in the form of pellets, characterised by that it has a coating containing copolymer of methacrylic acid and ethyl acrylate (1:1) and triethyl citrate, applied on a core consisting of the internal phase containing quetiapine fumarate or quetiapine, copolymer of methacrylic acid and ethyl acrylate (1:1), lactose, anhydrous crystalline maltose, and external phase containing talc and magnesium stearate. Method involves double wet granulation, drying, addition of lubricating and sliding substances, pressing and application of coating on the ready tablet.EFFECT: tablet atypical antipsychotic agents are effective and stable during storage.2 cl, 7 tbl, 6 ex

Biodegradable particles, material for vascular occlusion and method of producing biodegradable particles // 2587326
FIELD: medicine.SUBSTANCE: invention refers to medicine and is in biodegradable particles for use as material for embolisation of vessels. Particles are obtained by dissolving synthetic polymer poly basic carboxylic acid and condensation of water-soluble carbodiimide in aprotic organic solvent, addition of obtained solution in droplets to bad solvent for said aprotic polar solvent and by chemical linking reaction in obtained drops. Water content in particles makes 20-90 % in water-saturated state. Invention also relates to method of producing said particles and to material for embolisation vessels.EFFECT: technical result consists in fact that they have improved flexibility, brought to smaller aggregation between particles and can be easily delivered to selected point in blood vessel, without causing clogging of catheter; besides, particles retain shape that allows efficiency cause embolisation.10 cl, 1 tbl, 10 ex

Pharmaceutical composition containing biopharmaceutical drug // 2587056
FIELD: medicine; pharmacology.SUBSTANCE: group of inventions refers to Pharmacology and medicine and concerns stable pharmaceutical composition containing antibody against TNF-alpha and adipic acid or adipate, as well as using said composition for treating at least, one of the pathological state, selected from group including autoimmune diseases, infectious diseases, neoplastic disease, diseases of nervous system.EFFECT: group of inventions provides reduced aggregation antibodies in aqueous solutions and high stability during storage.9 cl, 13 tbl, 4 dwg

ethod for producing carrier particles for dry powders for inhalations // 2585101
FIELD: medicine.SUBSTANCE: described are carrier particles, a method for producing a carrier for a dry power pharmaceutical composition for inhalations, as well as the pharmaceutical composition in the form of a dry powder for inhalations. The active composition contains an active ingredient and carrier particles. The above carrier particles represent an alpha-lactose monohydrate with the mass diameter from 900 to 400 microns and are magnesium stearate-coated. The carrier particles are prepared by the method according to which the coating is deposited by a dry process in a mixer granulator with a high shear force at a rotational speed of 500 to 1,500 rpm.EFFECT: composition homogeneity in the environment comparable to that may occur when in use, the stronger adhesion of magnesium stearate to the particle carrier surface during inhalation, and therefore not suitable for systemic absorption that further increases the powder safety.13 cl, 13 tbl, 8 ex, 3 dwg

Composite collagen sponge and method of making same // 2584348
FIELD: medicine.SUBSTANCE: invention relates to medicine. Composite collagen sponge is intended for bleeding control, as well as for stimulation of growth and cell proliferation. Sponge comprises collagen, cell growth factors, and a protecting agent in an amount of 10-50 wt%, where protective agent contains amino acids, saccharides and albumin in weight ratio of 1-11:1.25-17.5:1-7.5. Method of producing sponge involves a step for virus inactivation, which includes two steps: first step is a viral inactivation organic solvent/detergent; second step is 30-120-minute solution treatment sponge on a water bath at 90-100 °C, and is carried out in presence of a protective agent. Sponge may be subjected to viral inactivation for a long time at high temperature, while bioactivity of collagen and growth factors is maintained.EFFECT: technical result consists in that sponge has water-absorbing capacity of more than 52 times based on weight of sponge and has modulus of elasticity greater than 70 N/cm2.7 cl, 3 ex, 11 tbl, 3 dwg

Using magnesium stearate in dry inhalation powder formulations // 2580890
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine. What is described is the use of magnesium stearate in an inhalation powder formulation containing carrier particles to inhibit or reduce chemical degradation of the active ingredient containing a hydrolysis-sensitive group. The active ingredient is specified in classes consisting of antimuscarinics, phosphodiesterase-4 inhibitors and steroids.EFFECT: in presence of magnesium stearate, the active ingredients have higher chemical storage-stability, particularly at high temperatures and/or high percentage of moisture.7 cl, 2 dwg, 3 tbl, 1 ex

Aerosol preparation based on fenoterol hydrobromide for treating respiratory diseases // 2577289
FIELD: medicine.SUBSTANCE: invention refers to medicine and pharmaceutical industry and concerns composition and method of producing the preparation of highly effective pharmaceutical substance and excipients allowing to form a fine particle aerosol to penetrate into the bronchi and pulmonary alveoli. Inhalation formulation for treating bronchial asthma and chronic obstructive pulmonary disease, containing as active component fenoterol hydrobromide, as a solvent-pure ethyl alcohol, a propellant, the propellant contains HFA-134a and/or HFA-227ea, as well as additionally contains an acidity regulator selected from hydrochloric acid, phosphoric and citric acids, as a substance which regulates the distribution profile, triethyl citrate.EFFECT: invention provides higher respirable fraction up to 35-40 % and obtaining optimum distribution profile of particles.2 cl, 1 dwg, 4 ex

Transdermally absorbable medicinal product // 2576612
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine. What is described is a transdermally absorbable medicinal product containing 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}benamidine or its salt, and a transdermal absorption enhancer.EFFECT: transdermally absorbable medicinal product effective in treating fungal infections, possesses a very high ability of for skin penetration and high antifungal activity; and the medicinal product significantly improves the patient's quality of life.13 cl, 2 dwg, 7 tbl, 58 ex

Pharmaceutical composition including amide derivative or pharmaceutically acceptable salt thereof // 2575829
FIELD: chemistry.SUBSTANCE: pharmaceutical composition includes a compound of formula (I) or a pharmaceutically acceptable salt thereof, an acid additive and inert filler. As the acid additive alginic acid or silicon dioxide is used.EFFECT: enhanced storage stability of the specified composition.9 cl, 19 ex, 7 tbl, 4 dwg
Agent for treating and preventing viral skin new growths // 2574953
FIELD: medicine.SUBSTANCE: what is described is an antiviral emulsion agent based on interferon inducer for topical application. The base contains Vaseline or Vaseline oil, T-2 emulsifier, as well as a solution of amphiphilic complex or single-chain high-polymeric RNA of Saccharomyces cerevisiae containing short double-stranded regions with oleic acid enriched with sodium oleate (up to 10%).EFFECT: prolonging the shelf life of the above agent.1 ex

ethod and formulation for producing 99m tc labelled 5-thio-d-glucose agent for radionuclide diagnosis // 2568888
FIELD: medicine.SUBSTANCE: method for producing 99m Tc-labelled 5-thio-D-glucose agent for radionuclide diagnosis involves producing a reaction mixture consisting of glucose derivative, tin (II) chloride dehydrate, hydrochloric acid and ascorbic acid in 1 ml of the solution, filtering and sterilising the produced solution and lyophilising the agent and sealing it in a bottle; the mixture is lyophilised without pre-freezing in liquid nitrogen. The reaction mixture contains 5-thio-D-glucose and water for injections in the following proportions: 5-thio-D-glucose 15 mg, tin (II) chloride dehydrate 0.150-0.175 mg, 0.05 M hydrochloric acid 200 mcl (0.36 mg), ascorbic acid 0.5 mg and water for injections 1 ml.EFFECT: creating the standard storage-stable formulation for producing the 99mTc-5-thio-D-glucose radiopharmaceutical to image a tumour by means of SPECT gamma-chamber and visualise biochemical changes of metabolism that is expected to promote accurate diagnosing and effective treatment of tumours.2 cl, 2 ex, 3 dwg, 1 tbl